 Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing novel oral biologics intended to act on cells in the small intestine for immunomodulatory effects. Evelos pipeline consists of four announced therapeutics 2 clinical-stage across 4 indications COVID-19, psoriasis, atopic dermatitis, general inflammation, and oncology and two pre-IND exploratory research programs neuro-inflammation and metabolic disorders. 